

…at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company's lead product, imlifidase, is an antibody-degrading enzyme being developed to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicine Agency (EMA). Hansa's research and development program is advancing the next generation of the Company's enzyme technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the US.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

Candidate	Indication	Preclinical	Phase 1[1]	Potentially Pivotal/ Phase 2[2]	Market Authorization	Marketed	Next anticipated milestone
Imlifidase	Kidney transplantation in highly sensitized patients	■	■	■	*)		EU: CHMP Opinion US: Initiation of clinical study to support BLA submission in 2023
	Anti-GBM (Goodpasture's disease)	■	■	□			Data read-out Q3 2020
	Antibody mediated kidney transplant rejection (AMR)	■	■	□			Complete enrollment
	GBS (Guillain Barre Syndrome)	■	■	□			Complete enrollment
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology	□					Development of CMC process / Tox studies
EnzE	Cancer immunotherapy	□					Research phase

■ Completed
□ Ongoing

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7).
[2] Lorant et al (2018) American Journal of Transplantation.
*) EMA: In imlifidase for kidney transplantation we have filed for conditional approval after completion of phase 2. A confirmatory study would need to be executed in case of approval.

FDA: Agreement with the FDA on a regulatory path forward in the US. New clinical study to support BLA submission by 2023.

STRATEGIC PRIORITIES

- Establish a commercial and medical infrastructure in Europe
- Attain marketing authorization in Europe for imlifidase as a treatment for highly sensitized patients to enable kidney transplantation
- Investigate the potential of imlifidase in autoimmune indications and post transplantation
- Advance a new set of immunomodulatory enzymes designed for repeat dosing in relapsing diseases (NiceR) into clinical development
- Explore potential combination therapies with imlifidase in oncology and in gene therapy in patients with neutralizing antibodies

MILESTONES & NEWS FLOW



HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	74 (~3/4 in R&D)
Key Executives	Ulf Wiinberg, Chairman
	Søren Tulstrup, President & CEO
	Donato Spota, SVP & CFO
	Christian Kjellman, SVP & CSO/COO

MARKET DATA (Dec 2019)

Market Cap	SEK ~3.5bn (USD ~350m)	
52 Week Range	SEK 62-304	
Avg. Daily Turnover	vol. 169k shares	
Shares Outstanding	41m	
Top 5 Shareholders	NXT2B	14.4%
	Invesco	6.3%
	Thomas Olausson	4.2%
	Avanza Pension	3.9%
	AP3	3.3%

STOCK CHART (3Y)

KEY FINANCIALS

SEKm	FY 2017	FY 2018	FY 2019*
Revenue	3m	3m	3m
R&D cost	-137m	-155m	-193m
Net profit	-177m	-248m	-360m
Cash & Short investment	616m	858m	601m
Operating Cash Flow	-150m	-205m	-335m
Employees	33	52	74

* Unaudited

CALENDAR

Feb 6, 2020	**Interim Report Oct-Dec 2019**
Feb 19-20, 2020	Road Show Kempen, Paris/Tel Aviv
Mar 2-3, 2020	Cowen Annual Health Care Conference, Boston
Mar 4, 2020	Carnegie Nordic Healthcare Seminar, Stockholm
Apr 2, 2020	**Annual Report 2019**
Apr 21-22, 2020	Kempen Life Sciences Conference, Amsterdam
Apr 28, 2020	**Interim Report Jan-Mar 2020**
May 18, 2020	UBS Global Healthcare Conference, NYC
May 19-20, 2020	RBC Global Healthcare Conference, NYC
May 26, 2020	ABG Life Science Summit, Stockholm

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269

Rolf Gulliksen
Head of Corp. Comms.
M: +46(0)733-328 634

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATE PATHOGENIC IgG

Origins from Streptococcus pyogenes



Imlifidase, a unique IgG antibody-cleaving enzyme



Imlifidase inactivates IgG in 2 hours



OUR EQUITY STORY

Targeting rare immunologic diseases with an IgG antibody-cleaving enzyme, addressing a high unmet medical need

Preparing for a potential commercialization in core European markets under conditional approval starting in H2 2020. MAA is currently under review by EMA. In the US a clear regulatory path has been agreed with the FDA that support potential submission of a BLA in 2023 under accelerated approval pathway

Evolution into a fully integrated biopharmaceutical company. We control the full value chain from early discovery through commercialization to maximize the value creation and capture

Leveraging our proprietary antibody cleaving enzyme technology. We are advancing our pipeline with three phase 2 programs in transplantation and acute autoimmune diseases.

A new set of modified enzymes is under development (NiceR) for repeat dosing; potentially enabling treatment in relapsing diseases and oncology.

We are exploring potential combination therapies in oncology and gene therapy in patients with neutralizing antibodies through potential partnerships



POTENTIAL INDICATION UNIVERSE